Lunai Bioworks (NASDAQ:LNAI) Rating Lowered to Sell at Wall Street Zen

Lunai Bioworks (NASDAQ:LNAI) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Sunday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Lunai Bioworks in a report on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Lunai Bioworks presently has an average rating of “Sell”.

Lunai Bioworks Trading Down 4.2%

Shares of NASDAQ:LNAI opened at $0.93 on Friday. The company’s 50-day moving average price is $1.10. The company has a market capitalization of $21.80 million, a P/E ratio of -13.29 and a beta of 0.37. Lunai Bioworks has a 12 month low of $0.81 and a 12 month high of $14.00.

Lunai Bioworks (NASDAQ:LNAI) last issued its quarterly earnings data on Friday, November 14th. The company reported $0.13 earnings per share (EPS) for the quarter.

Institutional Trading of Lunai Bioworks

A hedge fund recently bought a new stake in Lunai Bioworks stock. Millennium Management LLC purchased a new position in Lunai Bioworks Inc. (NASDAQ:LNAI) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned 0.87% of Lunai Bioworks as of its most recent SEC filing. 71.41% of the stock is currently owned by institutional investors and hedge funds.

Lunai Bioworks Company Profile

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.